A foreign investment fund is in advanced talks to acquire Israeli medical aesthetics firm InMode (INMD) for about $1.1B, or a 25% premium to its $882M valuation, which would result in the company being delisted, Calcalist reports. The potential deal comes well below its 2021 peak valuation of about $7B, the report notes. Shares of InMode are up 14% in premarket trading.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INMD: